Opinion|Videos|January 2, 2025
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has your life changed since receiving CAR T therapy? How has CAR T therapy impacted your overall quality of life compared with your previous treatments? Based on your experience, what advice would you give to other patients with multiple myeloma who are considering CAR T therapy?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5